Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency

References

• Eriksson S. Studies in alpha 1 antitrypsin deficiency. Acta Med Scand Suppl. 1965;432:1–85.
   PubMedGoogle Scholar
• Parr DG, Guest PG, Reynolds JH, et al. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2007;176(12):1215–1221. Epub 2007/ 09/18.
   PubMed Web of Science ®Google Scholar
• Townsend SA, Edgar RG, Ellis PR, et al. Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease. Aliment Pharmacol Ther. 2018;47(7):877–885. Epub 2018/ 02/16.
   PubMed Web of Science ®Google Scholar
• Morris H, Morgan MD, Wood AM, et al. ANCA-associated vasculitis is linked to carriage of the Z allele of alpha(1) antitrypsin and its polymers. Ann Rheum Dis. 2011;70(10):1851–1856. Epub 2011/ 08/09.
   PubMed Web of Science ®Google Scholar
• Stone H, Pye A, Stockley RA. Disease associations in alpha-1-antitrypsin deficiency. Respir Med. 2014;108(2):338–343. Epub 2013/ 11/02.
   PubMed Web of Science ®Google Scholar
• Wood AM, Harrison RM, Semple S, et al. Outdoor air pollution is associated with disease severity in alpha1-antitrypsin deficiency. Eur Respir J. 2009;34(2):346–353. Epub 2009/ 03/28.
   PubMed Web of Science ®Google Scholar
• Kim WJ, Wood AM, Barker AF, et al. Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency. Respir Res. 2012;13:16. Epub 2012/ 02/24.
   PubMed Web of Science ®Google Scholar
• Stockley RA, Turner AM. alpha-1-Antitrypsin deficiency: clinical variability, assessment, and treatment. Trends Mol Med. 2014;20(2):105–115. Epub 2014/ 01/02.
   PubMed Web of Science ®Google Scholar
• Carrell RW, Jeppsson JO, Laurell CB, et al. Structure and variation of human alpha 1-antitrypsin. Nature. 1982;298(5872):329–334.
   PubMed Web of Science ®Google Scholar
• Sloan B, Abrams WR, Meranze DR, et al. Emphysema induced in vitro and in vivo in dogs by a purified elastase from homologous leukocytes. Am Rev Respir Dis. 1981;124(3):295–301.
   PubMedGoogle Scholar
• Senior RM, Tegner H, Kuhn C, et al. The induction of pulmonary emphysema with human leukocyte elastase. Am Rev Respir Dis. 1977;116(3):469–475.
   PubMed Web of Science ®Google Scholar
• Snider GL, Lucey EC, Christensen TG, et al. Emphysema and bronchial secretory cell metaplasia induced in hamsters by human neutrophil products. Am Rev Respir Dis. 1984;129(1):155–160.
   PubMed Web of Science ®Google Scholar
• Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med. 1999;160(5 Pt 2):S49–52. Epub 1999/ 11/11.
   PubMed Web of Science ®Google Scholar
• Turino GM, Barker AF, Brantly ML, et al. Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. alpha 1-antitrypsin deficiency registry study group. Am J Respir Crit Care Med. 1996;154(6 Pt 1):1718–1725.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Dirksen A, Ferrarotti I, et al. European respiratory society statement: diagnosis and treatment of pulmonary disease in alpha1-antitrypsin deficiency. Eur Respir J. 2017;50:5:1700610. 1–24..
   Web of Science ®Google Scholar
• Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian thoracic society clinical practice guideline. Can Respir J. 2012;19(2):109–116. Epub 2012/ 04/27.
   PubMed Web of Science ®Google Scholar
• Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis. 2016;3(3):668–682. Epub 2016/ 06/06.
   PubMed Web of Science ®Google Scholar
• Lomas DA, Evans DL, Finch JT, et al. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992;357(6379):605–607. Epub 1992/ 06/18.
   PubMed Web of Science ®Google Scholar
• Salahuddin P. Genetic variants of alpha1-antitrypsin. Curr Protein Pept Sci. 2010;11(2):101–117. Epub 2009/ 09/16.
   PubMed Web of Science ®Google Scholar
• de Serres FJ, Blanco I. Prevalence of alpha1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. Ther Adv Respir Dis. 2012;6(5):277–295. Epub 2012/ 08/31.
   PubMed Web of Science ®Google Scholar
• Green CE, Vayalapra S, Hampson JA, et al. PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD. Thorax. 2015;70(10):939–945. Epub 2015/ 07/05.
   PubMed Web of Science ®Google Scholar
• Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med. 1986;314(12):736–739. Epub 1986/ 03/20.
   PubMed Web of Science ®Google Scholar
• Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med. 1976;294(24):1316–1321. Epub 1976/ 06/10.
   PubMed Web of Science ®Google Scholar
• Parmar JS, Mahadeva R, Reed BJ, et al. Polymers of alpha(1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am J Respir Cell Mol Biol. 2002;26(6):723–730. Epub 2002/ 05/30.
   PubMed Web of Science ®Google Scholar
• Petrache I, Fijalkowska I, Medler TR, et al. alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol. 2006;169(4):1155–1166. Epub 2006/ 09/28.
   PubMed Web of Science ®Google Scholar
• ISRCTN registry [database on the Internet]. BioMed Central. 2019. Available from: https://www.isrctn.com/
   Google Scholar
• Clinicaltrials.gov [database on the Internet]. US national library of medicine. 2019. Available from: https://clinicaltrials.gov/
   Google Scholar
• Gadek JE, Klein HG, Holland PV, et al. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest. 1981;68(5):1158–1165. Epub 1981/ 11/01.
   PubMed Web of Science ®Google Scholar
• Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987;316(17):1055–1062. Epub 1987/ 04/23.
   PubMed Web of Science ®Google Scholar
• Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1468–1472. Epub 1999/ 11/11.
   PubMed Web of Science ®Google Scholar
• Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The alpha-1-antitrypsin deficiency registry study group. Am J Respir Crit Care Med. 1998;158(1):49–59. Epub 1998/ 07/09.
   PubMed Web of Science ®Google Scholar
• Barros-Tizon JC, Torres ML, Blanco I, et al. Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy. Ther Adv Respir Dis. 2012;6(2):67–78. Epub 2012/ 02/23.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Burdon JG, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:360–368. Epub 2015/06/01.
   PubMed Web of Science ®Google Scholar
• Ma S, Lin YY, Cantor JO, et al. The effect of alpha-1 proteinase inhibitor on biomarkers of elastin degradation in alpha-1 antitrypsin deficiency: an analysis of the RAPID/RAPID extension trials. Chronic Obstr Pulm Dis. 2016;4(1):34–44. Epub 2017/ 08/30.
   PubMed Web of Science ®Google Scholar
• Edgar RG, Patel M, Bayliss S, et al. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review. Int J Chron Obstruct Pulmon Dis. 2017;12:1295–1308. Epub 2017/05/13.
   PubMed Web of Science ®Google Scholar
• Crossley D, Renton M, Khan M, et al. CT densitometry in emphysema: a systematic review of its clinical utility. Int J Chron Obstruct Pulmon Dis. 2018;13:547–563. Epub 2018/ 02/16.
   PubMed Web of Science ®Google Scholar
• Green CE, Parr DG, Edgar RG, et al. Lung density associates with survival in alpha 1 antitrypsin deficient patients. Respir Med. 2016;112:81–87. Epub 2016/ 02/15.
   PubMed Web of Science ®Google Scholar
• Piitulainen E, Bernspang E, Bjorkman S, et al. Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin. Eur J Clin Pharmacol. 2003;59(2):151–156. Epub 2003/ 05/03.
   PubMed Web of Science ®Google Scholar
• Zamora NP, Pla RV, Del Rio PG, et al. Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: from pharmacokinetic analysis to individualizing therapy. Ann Pharmacother. 2008;42(5):640–646. Epub 2008/ 04/17.
   PubMed Web of Science ®Google Scholar
• Stocks JM, Brantly ML, Wang-Smith L, et al. Pharmacokinetic comparability of prolastin(R)-C to prolastin(R) in alpha(1)-antitrypsin deficiency: a randomized study. BMC Clin Pharmacol. 2010;10:13. Epub 2010/ 10/06.
   PubMedGoogle Scholar
• Soy D, de la Roza C, Lara B, et al. Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics. Thorax. 2006;61(12):1059–1064. Epub 2006/ 08/25.
   PubMed Web of Science ®Google Scholar
• Sorrells S, Camprubi S, Griffin R, et al. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency. Respir Med. 2015;109(4):490–499. Epub 2015/ 03/03.
   PubMed Web of Science ®Google Scholar
• Zhu W, Li L, Deng M, et al. Oxidation-resistant and thermostable forms of alpha-1 antitrypsin from Escherichia coli inclusion bodies. FEBS Open Bio. 2018;8(10):1711–1721. Epub 2018/ 10/20.
   PubMed Web of Science ®Google Scholar
• Bischoff R, Speck D, Lepage P, et al. Purification and biochemical characterization of recombinant alpha 1-antitrypsin variants expressed in Escherichia coli. Biochemistry. 1991;30(14):3464–3472.
   PubMed Web of Science ®Google Scholar
• Bottomley SP, Stone SR. Protein engineering of chimeric Serpins: an investigation into effects of the serpin scaffold and reactive centre loop length. Protein Eng. 1998;11(12):1243–1247.
   PubMedGoogle Scholar
• Courtney M, Buchwalder A, Tessier LH, et al. High-level production of biologically active human alpha 1-antitrypsin in Escherichia coli. Proc Natl Acad Sci U S A. 1984;81(3):669–673.
   PubMed Web of Science ®Google Scholar
• Karnaukhova E, Ophir Y, Golding B, et al., editors. Recombinant human alpha 1 proteinase inhibitor: glycosylation, stability and biological activity. 10th FDA science forum: the critical path from concept to consumer. Washington DC; 2004.
   Google Scholar
• Krishnan B, Hedstrom L, Hebert DN, et al. Expression and purification of active recombinant human alpha-1 antitrypsin (AAT) from Escherichia coli. Methods Mol Biol. 2017;1639:195–209. Epub 2017/ 07/29.
   PubMedGoogle Scholar
• Casolaro MA, Fells G, Wewers M, et al. Augmentation of lung antineutrophil elastase capacity with recombinant human alpha-1-antitrypsin. J Appl Physiol. 1987;63(5):2015–2023.
   PubMed Web of Science ®Google Scholar
• Kwon KS, Song M, Yu MH. Purification and characterization of alpha 1-antitrypsin secreted by recombinant yeast Saccharomyces diastaticus. J Biotechnol. 1995;42(3):191–195.
   PubMed Web of Science ®Google Scholar
• Tamer IM, Chisti Y. Production and recovery of recombinant protease inhibitor alpha 1 antitrypsin. Enzyme Microb Technol. 2001;29:611–620.
   Web of Science ®Google Scholar
• Sandoval C, Curtis H, Congote LF. Enhanced proliferative effects of a baculovirus-produced fusion protein of insulin-like growth factor and alpha(1)-proteinase inhibitor and improved anti-elastase activity of the inhibitor with glutamate at position 351. Protein Eng. 2002;15(5):413–418.
   PubMedGoogle Scholar
• Terashima M, Ejiri Y, Hashikawa N, et al. Effects of sugar concentration on recombinant human alpha(1)-antitrypsin production by genetically engineered rice cell. Biochem Eng J. 2000;6(3):201–205.
   PubMed Web of Science ®Google Scholar
• Huang J, Sutliff TD, Wu L, et al. Expression and purification of functional human alpha-1-antitrypsin from cultured plant cells. Biotechnol Prog. 2001;17(1):126–133.
   PubMed Web of Science ®Google Scholar
• Zhang N, Wright T, Caraway P, et al. Enhanced secretion of human alpha1-antitrypsin expressed with a novel glycosylation module in tobacco BY-2 cell culture. Bioengineered. 2019. Epub 2019/ 04/09.
   Web of Science ®Google Scholar
• Silberstein DZ, Karuppanan K, Aung HH, et al. An oxidation-resistant, recombinant alpha-1 antitrypsin produced in Nicotiana benthamiana. Free Radic Biol Med. 2018;120:303–310. Epub 2018/ 03/20.
   PubMed Web of Science ®Google Scholar
• Huang TK, Falk BW, Dandekar AM, et al. Enhancement of recombinant protein production in transgenic nicotiana benthamiana plant cell suspension cultures with co-cultivation of agrobacterium containing silencing suppressors. Int J Mol Sci. 2018;19:6 :1561.
   Web of Science ®Google Scholar
• Morifuji Y, Xu J, Karasaki N, et al. Expression, purification, and characterization of recombinant human alpha1-antitrypsin produced using silkworm-baculovirus expression system. Mol Biotechnol. 2018;60(12):924–934. Epub 2018/ 10/12.
   PubMed Web of Science ®Google Scholar
• Massoud M, Bischoff R, Dalemans W, et al. Expression of active recombinant human alpha 1-antitrypsin in transgenic rabbits. J Biotechnol. 1991;18(3):193–203.
   PubMed Web of Science ®Google Scholar
• Moens A, Betteridge KJ, Brunet A, et al. Low levels of chimerism in rabbit fetuses produced from preimplantation embryos microinjected with fetal gonadal cells. Mol Reprod Dev. 1996;43(1):38–46. Epub 1996/ 01/01.
   PubMed Web of Science ®Google Scholar
• Archibald AL, McClenaghan M, Hornsey V, et al. High-level expression of biologically active human alpha 1-antitrypsin in the milk of transgenic mice. Proc Natl Acad Sci U S A. 1990;87(13):5178–5182.
   PubMed Web of Science ®Google Scholar
• Bischoff R, Degryse E, Perraud F, et al. A 17.6 kbp region located upstream of the rabbit WAP gene directs high level expression of a functional human protein variant in transgenic mouse milk. FEBS Lett. 1992;305(3):265–268. Epub 1992/ 07/06.
   PubMed Web of Science ®Google Scholar
• Zbikowska HM, Soukhareva N, Behnam R, et al. Uromodulin promoter directs high-level expression of biologically active human alpha1-antitrypsin into mouse urine. Biochem J. 2002;365(Pt 1):7–11.
   PubMedGoogle Scholar
• Carver AS, Dalrymple MA, Wright G, et al. Transgenic livestock as bioreactors: stable expression of human alpha-1-antitrypsin by a flock of sheep. Biotechnol (N Y). 1993;11(11):1263–1270.
   PubMedGoogle Scholar
• Wright G, Carver A, Cottom D, et al. High level expression of active human alpha-1-antitrypsin in the milk of transgenic sheep. Biotechnol (N Y). 1991;9(9):830–834.
   PubMedGoogle Scholar
• Spencer LT, Humphries JE, Brantly ML. Antibody response to aerosolized transgenic human alpha1-antitrypsin. N Engl J Med. 2005;352(19):2030–2031.
   PubMed Web of Science ®Google Scholar
• Ross D, Brown T, Harper R, et al. Production and characterization of a novel human recombinant alpha-1-antitrypsin in PER.C6 cells. J Biotechnol. 2012;162(2–3):262–273. Epub 2012/ 10/06.
   PubMed Web of Science ®Google Scholar
• Wang Z, Hilder TL, Drift KV, et al. Structural characterization of recombinant alpha-1-antitrypsin expressed in a human cell line. Anal Biochem. 2013;437:20–28. Epub 2013/ 03/07.
   Web of Science ®Google Scholar
• Jaberie H, Naghibalhossaini F. Recombinant production of native human alpha-1-antitrypsin protein in the liver HepG2 cells. Biotechnol Lett. 2016;38(10):1683–1690. Epub 2016/ 06/18.
   PubMed Web of Science ®Google Scholar
• Lee S, Lee Y, Hong K, et al. Effect of recombinant alpha1-antitrypsin Fc-fused (AAT-Fc)protein on the inhibition of inflammatory cytokine production and streptozotocin-induced diabetes. Mol Med. 2013;19:65–71. Epub 2013/ 04/05.
   PubMed Web of Science ®Google Scholar
• Toldo S, Mauro AG, Marchetti C, et al. Recombinant human alpha-1 antitrypsin-fc fusion protein reduces mouse myocardial inflammatory injury after ischemia-reperfusion independent of elastase inhibition. J Cardiovasc Pharmacol. 2016;68(1):27–32. Epub 2016/ 03/06.
   PubMed Web of Science ®Google Scholar
• Joosten LA, Crisan TO, Azam T, et al. Alpha-1-anti-trypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1beta and by the induction of endogenous IL-1Ra. Ann Rheum Dis. 2016;75(6):1219–1227. Epub 2015/ 07/16.
   PubMed Web of Science ®Google Scholar
• Sabbagh D, Barmayehvar B, Nguyen T, et al. Managing pannicultis in AATD: a systematic review of the evidence behind treatment. World J Dermatol. 2018;7:1–8.
   Google Scholar
• Hubbard RC, Sellers S, Czerski D, et al. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA. 1988;260(9):1259–1264. Epub 1988/ 09/02.
   PubMed Web of Science ®Google Scholar
• Hubbard RC, Crystal RG. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Lung. 1990;168(Suppl):565–578. Epub 1990/01/01.
   PubMed Web of Science ®Google Scholar
• Kropp J, Wencker M, Hotze A, et al. Inhalation of [123I]alpha1-protease inhibitor: toward a new therapeutic concept of alpha1-protease inhibitor deficiency? J Nucl Med. 2001;42(5):744–751. Epub 2001/ 05/05.
   PubMed Web of Science ®Google Scholar
• Brand P, Beckmann H, Maas Enriquez M, et al. Peripheral deposition of alpha1-protease inhibitor using commercial inhalation devices. Eur Respir J. 2003;22(2):263–267. Epub 2003/ 09/04.
   PubMed Web of Science ®Google Scholar
• Kamada announces FDA acceptance of Inhaled AAT program path forward. 2019 Aug 8. Available from: https://www.kamada.com/news/kamada-announces-fda-acceptance-of-inhaled-aat-program-path-forward/
   Google Scholar
• Cantor JO, Shteyngart B, Cerreta JM, et al. The effect of hyaluronan on elastic fiber injury in vitro and elastase-induced airspace enlargement in vivo. Proc Soc Exp Biol Med. 2000;225(1):65–71. Epub 2000/ 09/21.
   PubMed Web of Science ®Google Scholar
• Cantor JO, Cerreta JM, Ochoa M, et al. Aerosolized hyaluronan limits airspace enlargement in a mouse model of cigarette smoke-induced pulmonary emphysema. Exp Lung Res. 2005;31(4):417–430. Epub 2005/ 07/20.
   PubMed Web of Science ®Google Scholar
• Cantor J, Ma S, Turino G. A pilot clinical trial to determine the safety and efficacy of aerosolized hyaluronan as a treatment for COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2747–2752. Epub 2017/ 10/28.
   PubMed Web of Science ®Google Scholar
• Cantor J, Armand G, Turino G. Lung hyaluronan levels are decreased in alpha-1 antiprotease deficiency COPD. Respir Med. 2015;109(5):656–659. Epub 2015/ 04/12.
   PubMed Web of Science ®Google Scholar
• Guo S, Booten SL, Aghajan M, et al. Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice. J Clin Invest. 2014;124(1):251–261. Epub 2013/ 12/21.
   PubMed Web of Science ®Google Scholar
• Turner AM, Stolk J, Bals R, et al. Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients. J Hepatol. 2018;69(2):378–384. Epub 2018/ 03/25.
   PubMed Web of Science ®Google Scholar
• Arrowhead pharmaceuticals receives FDA clearance to begin phase 2/3 study of ARO-AAT for treatment of alpha-1 liver disease. Arrowhead Pharm. 2019; Available from: http://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-receives-fda-clearance-begin-phase-23
   Google Scholar
• Schwabe C, Hamilton J, Christianson D, et al. A phase I single and multiple dose escalating study to evaluate the safety, tolerability, pharmacokinetics and effect of ARO-AAT on serum AAT levels in normal adult volunteers. Hepatology. 2018;68(S1):LB–9.
   Google Scholar
• Fregonese L, Stolk J, Frants RR, et al. Alpha-1 antitrypsin null mutations and severity of emphysema. Respir Med. 2008;102(6):876–884. Epub 2008/ 03/21.
   PubMed Web of Science ®Google Scholar
• Mizumura K, Cloonan SM, Haspel JA, et al. The emerging importance of autophagy in pulmonary diseases. Chest. 2012;142(5):1289–1299. Epub 2012/ 11/08.
   PubMed Web of Science ®Google Scholar
• Hidvegi T, Ewing M, Hale P, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science. 2010;329(5988):229–232. Epub 2010/ 06/05.
   PubMed Web of Science ®Google Scholar
• Lykavieris P, Ducot B, Lachaux A, et al. Liver disease associated with ZZ alpha1-antitrypsin deficiency and ursodeoxycholic acid therapy in children. J Pediatr Gastroenterol Nutr. 2008;47(5):623–629. Epub 2008/ 10/29.
   PubMed Web of Science ®Google Scholar
• Kaushal S, Annamali M, Blomenkamp K, et al. Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model. Exp Biol Med (Maywood). 2010;235(6):700–709. Epub 2010/ 06/01.
   PubMed Web of Science ®Google Scholar
• Gosai SJ, Kwak JH, Luke CJ, et al. Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin alpha1-antitrypsin Z. PLoS One. 2010;5(11):e15460. Epub 2010/ 11/26.
   PubMed Web of Science ®Google Scholar
• Turner AM. Gene Therapy. In: Kalsheker N, Stockley RA, editors. Alpha 1 antitrypsin deficiency: biology, diagnosis, clinical significance and emerging therapies. Elsevier; Academic Press USA; 2017. p. 262.
   Google Scholar
• Brantly ML, Spencer LT, Humphries M, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther. 2006;17(12):1177–1186. Epub 2006/ 11/23.
   PubMed Web of Science ®Google Scholar
• Brantly ML, Chulay JD, Wang L, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A. 2009;106(38):16363–16368. Epub 2009/ 08/27.
   PubMed Web of Science ®Google Scholar
• Kang W, Wang L, Harrell H, et al. An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes. Gene Ther. 2009;16(2):229–239. Epub 2008/ 10/17.
   PubMed Web of Science ®Google Scholar
• Flotte TR, Trapnell BC, Humphries M, et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther. 2011;22(10):1239–1247. Epub 2011/ 05/26.
   PubMed Web of Science ®Google Scholar
• Mueller C, Chulay JD, Trapnell BC, et al. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest. 2013;123(12):5310–5318. Epub 2013/ 11/16.
   PubMed Web of Science ®Google Scholar
• Gruntman AM, Gernoux G, Tang Q, et al. Bridging from intramuscular to limb perfusion delivery of rAAV: optimization in a non-human primate study. Mol Ther Methods Clin Dev. 2019;13:233–242. Epub 2019/ 03/05.
   PubMed Web of Science ®Google Scholar
• De BP, Heguy A, Hackett NR, et al. High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol Ther. 2006;13(1):67–76. Epub 2005/ 11/02.
   PubMed Web of Science ®Google Scholar
• Brigham KL, Lane KB, Meyrick B, et al. Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy. Hum Gene Ther. 2000;11(7):1023–1032. Epub 2000/ 05/16.
   PubMed Web of Science ®Google Scholar
• Wilson AA, Kwok LW, Hovav AH, et al. Sustained expression of alpha1-antitrypsin after transplantation of manipulated hematopoietic stem cells. Am J Respir Cell Mol Biol. 2008;39(2):133–141. Epub 2008/ 03/08.
   PubMed Web of Science ®Google Scholar
• Li H, Zhang B, Lu Y, et al. Adipose tissue-derived mesenchymal stem cell-based liver gene delivery. J Hepatol. 2011;54(5):930–938. Epub 2010/ 12/21.
   PubMed Web of Science ®Google Scholar
• Li H, Lu Y, Witek RP, et al. Ex vivo transduction and transplantation of bone marrow cells for liver gene delivery of alpha1-antitrypsin. Mol Ther. 2010;18(8):1553–1558. Epub 2010/ 06/17.
   PubMed Web of Science ®Google Scholar
• Ghaedi M, Lotfi AS, Soleimani M. Establishment of lentiviral-vector-mediated model of human alpha-1 antitrypsin delivery into hepatocyte-like cells differentiated from mesenchymal stem cells. Tissue Cell. 2010;42(3):181–189. Epub 2010/ 05/04.
   PubMed Web of Science ®Google Scholar
• Yusa K, Rashid ST, Strick-Marchand H, et al. Targeted gene correction of alpha1-antitrypsin deficiency in induced pluripotent stem cells. Nature. 2011;478(7369):391–394. Epub 2011/ 10/14.
   PubMed Web of Science ®Google Scholar
• Gentzsch M, Mall MA. Ion channel modulators in cystic fibrosis. Chest. 2018;154(2):383–393. Epub 2018/ 05/12.
   PubMed Web of Science ®Google Scholar
• Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci U S A. 2000;97(4):1796–1801.
   PubMed Web of Science ®Google Scholar
• Devlin GL, Parfrey H, Tew DJ, et al. Prevention of polymerization of M and Z alpha1-antitrypsin (alpha1-AT) with trimethylamine N-oxide. Implications for the treatment of alpha1-at deficiency. Am J Respir Cell Mol Biol. 2001;24(6):727–732.
   PubMed Web of Science ®Google Scholar
• Teckman JH. Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study. J Pediatr Gastroenterol Nutr. 2004;39(1):34–37. Epub 2004/ 06/10.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Peralta RP, Leonard S, Harvey R, et al. 4-phenyl butyrate mediated secretion rescue in patients with alpha 1-antitrypsin (AAT) deficiency: A pilot study. Hepatology. 2006;44(4):211A.
   Web of Science ®Google Scholar
• Schmidt BZ, Perlmutter DH. Grp78, Grp94, and Grp170 interact with alpha1-antitrypsin mutants that are retained in the endoplasmic reticulum. Am J Physiol Gastrointest Liver Physiol. 2005;289(3):G444–55.
   PubMed Web of Science ®Google Scholar
• Chang YP, Mahadeva R, Chang WS, et al. Identification of a 4-mer peptide inhibitor that effectively blocks the polymerization of pathogenic Z alpha1-antitrypsin. Am J Respir Cell Mol Biol. 2006;35(5):540–548. Epub 2006/ 06/17.
   PubMed Web of Science ®Google Scholar
• Mahadeva R, Dafforn TR, Carrell RW, et al. 6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z alpha(1)-antitrypsin-related cirrhosis. J Biol Chem. 2002;277(9):6771–6774.
   PubMed Web of Science ®Google Scholar
• Parfrey H, Dafforn TR, Belorgey D, et al. Inhibiting polymerization: new therapeutic strategies for Z alpha1-antitrypsin-related emphysema. Am J Respir Cell Mol Biol. 2004;31(2):133–139.
   PubMed Web of Science ®Google Scholar
• Mallya M, Phillips RL, Saldanha SA, et al. Small molecules block the polymerization of Z alpha1-antitrypsin and increase the clearance of intracellular aggregates. J Med Chem. 2007;50(22):5357–5363. Epub 2007/ 10/09.
   PubMed Web of Science ®Google Scholar
• Alam S, Wang J, Janciauskiene S, et al. Preventing and reversing the cellular consequences of Z alpha-1 antitrypsin accumulation by targeting s4A. J Hepatol. 2012;57(1):116–124. Epub 2012/ 03/20.
   PubMed Web of Science ®Google Scholar
• New collaboration to develop treatments for liver disease. University of Cambridge; 2012. Available from: https://www.cam.ac.uk/research/news/new-collaboration-to-develop-treatments-for-liver-disease
   Google Scholar
• University College London Collaboration Aims to Treat. Alpha-1-antitrypsin deficiency. Glao Smith Kline. University College London; 2017. Available from: http://www.dpac.gsk.com/case-studies-universitycollegelondon.html
   Google Scholar